150 related articles for article (PubMed ID: 30963795)
1. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells.
Zhang Q; Di C; Yan J; Wang F; Qu T; Wang Y; Chen Y; Zhang X; Liu Y; Yang H; Zhang H
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1273-1280. PubMed ID: 30963795
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines.
Jorge J; Petronilho S; Alves R; Coucelo M; Gonçalves AC; Nascimento Costa JM; Sarmento-Ribeiro AB
Invest New Drugs; 2020 Apr; 38(2):369-377. PubMed ID: 31147807
[TBL] [Abstract][Full Text] [Related]
4. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
Kim Guisbert KS; Guisbert E
PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
[TBL] [Abstract][Full Text] [Related]
5. Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.
Effenberger KA; Anderson DD; Bray WM; Prichard BE; Ma N; Adams MS; Ghosh AK; Jurica MS
J Biol Chem; 2014 Jan; 289(4):1938-47. PubMed ID: 24302718
[TBL] [Abstract][Full Text] [Related]
6. Biological validation that SF3b is a target of the antitumor macrolide pladienolide.
Yokoi A; Kotake Y; Takahashi K; Kadowaki T; Matsumoto Y; Minoshima Y; Sugi NH; Sagane K; Hamaguchi M; Iwata M; Mizui Y
FEBS J; 2011 Dec; 278(24):4870-80. PubMed ID: 21981285
[TBL] [Abstract][Full Text] [Related]
7. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric analysis identifies changes in S and M phases as novel cell cycle alterations induced by the splicing inhibitor isoginkgetin.
Vanzyl EJ; Rick KRC; Blackmore AB; MacFarlane EM; McKay BC
PLoS One; 2018; 13(1):e0191178. PubMed ID: 29338026
[TBL] [Abstract][Full Text] [Related]
9. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
[TBL] [Abstract][Full Text] [Related]
10. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping.
Wu G; Fan L; Edmonson MN; Shaw T; Boggs K; Easton J; Rusch MC; Webb TR; Zhang J; Potter PM
RNA; 2018 Aug; 24(8):1056-1066. PubMed ID: 29844105
[TBL] [Abstract][Full Text] [Related]
12. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
[TBL] [Abstract][Full Text] [Related]
13. Chemical Inhibition of Pre-mRNA Splicing in Living Saccharomyces cerevisiae.
Hansen SR; Nikolai BJ; Spreacker PJ; Carrocci TJ; Hoskins AA
Cell Chem Biol; 2019 Mar; 26(3):443-448.e3. PubMed ID: 30639260
[TBL] [Abstract][Full Text] [Related]
14. Titration of SF3B1 Activity Reveals Distinct Effects on the Transcriptome and Cell Physiology.
Kim Guisbert KS; Mossiah I; Guisbert E
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348896
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of splicing factor poly(rC)-binding protein 1 elicits cycle arrest, apoptosis induction, and p73 splicing in human cervical carcinoma cells.
Chen Y; Dou Z; Chen X; Zhao D; Che T; Su W; Qu T; Zhang T; Xu C; Lei H; Li Q; Zhang H; Di C
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3475-3484. PubMed ID: 35896897
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
[TBL] [Abstract][Full Text] [Related]
17. Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells.
Anufrieva KS; Shender VО; Arapidi GP; Pavlyukov MS; Shakhparonov MI; Shnaider PV; Butenko IO; Lagarkova MA; Govorun VM
Genome Med; 2018 Jun; 10(1):49. PubMed ID: 29950180
[TBL] [Abstract][Full Text] [Related]
18. Diallyl disulfide enhances carbon ion beams-induced apoptotic cell death in cervical cancer cells through regulating Tap73 /ΔNp73.
Di C; Sun C; Li H; Si J; Zhang H; Han L; Zhao Q; Liu Y; Liu B; Miao G; Gan L; Liu Y
Cell Cycle; 2015; 14(23):3725-33. PubMed ID: 26505313
[TBL] [Abstract][Full Text] [Related]
19. Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells.
Gao Y; Trivedi S; Ferris RL; Koide K
Sci Rep; 2014 Aug; 4():6098. PubMed ID: 25139387
[TBL] [Abstract][Full Text] [Related]
20. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
